|
|
Article: Anadys Pharmaceuticals and LG Life Sciences Report Positive Data From Phase II Clinical Trial of ANA380 in Patients With Lamivudine-Resistant Hepatitis B Virus Infection.
- Article from:
- PR Newswire
- Article date:
- December 13, 2004
CopyrightCOPYRIGHT 2004 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Interim Data Presented at APASL Conference Demonstrate Potent Activity Against Lamivudine-Resistant Strains
Anadys Pharmaceuticals, Inc. and LG Life Sciences, Ltd. today reported positive interim data from a Phase II clinical trial of ANA380 (LB80380) in patients infected with lamivudine-resistant hepatitis B virus (HBV) at the Asian Pacific Association for the Study of the Liver (APASL) Conference in New Delhi, India.
Ching-Lung Lai, M.D., Professor in the Department of Medicine at the University of Hong Kong and co-investigator of the study, reported that oral administration of ANA380 over 12 weeks reduced viral load by an average of 3.0 log10units, ...